<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04045366</url>
  </required_header>
  <id_info>
    <org_study_id>S54510</org_study_id>
    <nct_id>NCT04045366</nct_id>
  </id_info>
  <brief_title>Impact of Capillary Leak and Hypoalbuminemia on PK/PD of Anidulafungin and Caspofungin in Critically Ill Patients</brief_title>
  <official_title>Impact of Capillary Leak and Hypoalbuminemia on PK/PD of Anidulafungin and Caspofungin in Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study will explore the pharmacokinetic exposure and pharmacodynamics of the
      echinocandins (caspofungin or anidulafungin) in critically ill patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This non-randomized, monocenter pharmacokinetic study will be carried out in critically ill
      patients receiving multiple dose treatment with echinocandins (caspofungin or anidulafungin).

      The pharmacokinetics and pharmacodynamics of the echinocandins in plasma and BAL will be
      determined. Especially, the relative contributions of two pathophysiological alterations
      (capillary leak and hypoalbuminemia) encountered in critically ill patients, will be
      explored.

      Also other correlating covariates will be identified to provide a rationale for optimal
      dosing strategy in critically ill patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2012</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>July 2020</time_frame>
    <description>The area under the concentration-time curve will be calculated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (T1/2)</measure>
    <time_frame>July 2020</time_frame>
    <description>The half-life will be calculated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution (Vd)</measure>
    <time_frame>July 2020</time_frame>
    <description>The volume of distribution will be calculated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>July 2020</time_frame>
    <description>The clearance will be calculated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration</measure>
    <time_frame>July 2020</time_frame>
    <description>The median maximum plasma concentration will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum plasma concentration</measure>
    <time_frame>July 2020</time_frame>
    <description>The median minimum plasma concentration will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average plasma concentration</measure>
    <time_frame>July 2020</time_frame>
    <description>The average plasma concentration will be calculated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influence of serum creatinin (mg/dL) on echinocandin-exposure</measure>
    <time_frame>July 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of glomerular filtration rate (ml/min) on echinocandin-exposure</measure>
    <time_frame>July 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of on bilirubin on echinocandin-exposure</measure>
    <time_frame>July 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of gamma-GT on echinocandin-exposure</measure>
    <time_frame>July 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of alkaline phosphatase on echinocandin-exposure</measure>
    <time_frame>July 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of AST on echinocandin-exposure</measure>
    <time_frame>July 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of ALT on echinocandin-exposure</measure>
    <time_frame>July 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of SOFA ( sequential organ failure assessment) score on echinocandin-exposure</measure>
    <time_frame>July 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of APACHE II (Acute Physiology and Chronic Health Evaluation II) score on echinocandin-exposure</measure>
    <time_frame>July 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of total protein on echinocandin-exposure</measure>
    <time_frame>July 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of serum albumin on echinocandin-exposure</measure>
    <time_frame>July 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of Ang-1 on echinocandin-exposure</measure>
    <time_frame>July 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of Ang-2 on echinocandin-exposure</measure>
    <time_frame>July 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of VEGF on echinocandin-exposure</measure>
    <time_frame>July 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of inflammation (CRP) on echinocandin-exposure</measure>
    <time_frame>July 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of fluid balance (mL) on echinocandin-exposure</measure>
    <time_frame>July 2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of prothrombin time on echinocandin-exposure</measure>
    <time_frame>July 2020</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Critically Ill Patients</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sample collection</intervention_name>
    <description>Plasma and BAL sample collection</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and BAL (bronchoalveolar lavage)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment with anidulafungin or caspofungin

          -  Admitted to an ICU ward

        Exclusion Criteria:

          -  &lt; 18 years

          -  DNR 2 or 3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabel Spriet, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabel Spriet, PharmD, PhD</last_name>
    <phone>+32 16 34 30 80</phone>
    <email>isabel.spriet@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruth Van Daele, PharmD</last_name>
    <phone>+32 16 34 30 80</phone>
    <email>ruth.vandaele@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Spriet, PharmD, PhD</last_name>
      <phone>+32 16 34 30 80</phone>
      <email>isabel.spriet@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Ruth Van Daele, PharmD</last_name>
      <phone>+32 16 34 30 80</phone>
      <email>ruth.vandaele@uzleuven.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 14, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>August 2, 2019</last_update_submitted>
  <last_update_submitted_qc>August 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Echinocandins</keyword>
  <keyword>Critically ill patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoalbuminemia</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

